Lee Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-150
| Closed | -$19.8K | – | 583 |
|
|
2023
Q4 | $19.8K | Hold |
150
| – | – | ﹤0.01% | 322 |
|
|
2023
Q3 | $16.9K | Hold |
150
| – | – | ﹤0.01% | 328 |
|
|
2023
Q2 | $14.1K | Hold |
150
| – | – | ﹤0.01% | 357 |
|
|
2023
Q1 | $15.2K | Sell |
150
-10
| -6% | -$1.01K | ﹤0.01% | 354 |
|
|
2022
Q4 | $19.1K | Hold |
160
| – | – | ﹤0.01% | 347 |
|
|
2022
Q3 | $17K | Sell |
160
-47
| -23% | -$4.99K | ﹤0.01% | 352 |
|
|
2022
Q2 | $20K | Buy |
207
+2
| +1% | +$193 | ﹤0.01% | 335 |
|
|
2022
Q1 | $19K | Buy |
205
+21
| +11% | +$1.95K | ﹤0.01% | 349 |
|
|
2021
Q4 | $16K | Buy |
184
+24
| +15% | +$2.09K | ﹤0.01% | 409 |
|
|
2021
Q3 | $15K | Hold |
160
| – | – | ﹤0.01% | 372 |
|
|
2021
Q2 | $16K | Buy |
160
+20
| +14% | +$2K | ﹤0.01% | 347 |
|
|
2021
Q1 | $14K | Hold |
140
| – | – | ﹤0.01% | 355 |
|
|
2020
Q4 | $13K | Hold |
140
| – | – | ﹤0.01% | 345 |
|
|
2020
Q3 | $13K | Hold |
140
| – | – | ﹤0.01% | 361 |
|
|
2020
Q2 | $17K | Hold |
140
| – | – | ﹤0.01% | 297 |
|
|
2020
Q1 | $12K | Buy |
140
+25
| +22% | +$2.14K | ﹤0.01% | 272 |
|
|
2019
Q4 | $12K | Hold |
115
| – | – | ﹤0.01% | 318 |
|
|
2019
Q3 | $10K | Buy |
115
+10
| +10% | +$870 | ﹤0.01% | 343 |
|
|
2019
Q2 | $9K | Hold |
105
| – | – | ﹤0.01% | 369 |
|
|
2019
Q1 | $9K | Hold |
105
| – | – | ﹤0.01% | 357 |
|
|
2018
Q4 | $7K | Buy |
+105
| New | +$7K | ﹤0.01% | 334 |
|